A 42-year-old man with a 10-year history of chronic hepatitis B (HBsAg-positive) presents with worsening jaundice, ascites, and encephalopathy. His liver function tests show INR 2.8 and albumin 2.1 g/dL, consistent with decompensated cirrhosis. Which investigation is most appropriate to assess his current viral replication status and guide antiviral therapy?

## Assessment of HBV Replication and Antiviral Therapy Guidance ### Clinical Context The patient has chronic HBV with decompensated cirrhosis. Management of advanced liver disease requires knowledge of **viral load** to determine urgency and type of antiviral therapy. Serological markers alone do not quantify replication. ### HBV Serological and Virological Markers | Marker | Meaning | Acute | Chronic | Immunity | Guides Therapy? | |--------|---------|-------|---------|----------|------------------| | **HBsAg** | Infection marker | Present | Present | Absent | No (binary) | | **Anti-HBc** | Exposure history | Present | Present | Present | No (binary) | | **HBeAg** | High replication | Often present | Variable | Absent | Indirect | | **Anti-HBe** | Lower replication | Absent | Variable | Absent | Indirect | | **HBV DNA (PCR)** | **Viral load** | **Quantified** | **Quantified** | **Absent** | **Yes (quantitative)** | | **Anti-HBs** | Immunity/recovery | Absent | Absent | Present | No | **Key Point:** HBV DNA by quantitative PCR is the **gold standard** for assessing viral replication and is **essential for guiding antiviral therapy**. It provides the **absolute viral load** in copies/mL or IU/mL, which directly determines treatment initiation and drug selection. ### Why HBV DNA (Quantitative PCR)? 1. **Quantifies viral replication** — provides exact copy number 2. **Guides treatment decisions** — thresholds vary by HBeAg status and fibrosis stage 3. **Monitors response** — tracks viral suppression during therapy 4. **Predicts prognosis** — higher viral load correlates with worse outcomes in cirrhosis 5. **Mandatory before therapy** — all guidelines (AASLD, EASL, APASL) require baseline HBV DNA ### Clinical Pearl **High-Yield:** In any patient with chronic HBV being considered for antiviral therapy, **HBV DNA quantification by PCR is mandatory**. It is the only investigation that determines whether treatment is indicated and which agent to use. In this patient with decompensated cirrhosis, high viral load would necessitate immediate antiviral therapy (nucleoside/nucleotide analogues or peginterferon, depending on HBeAg status and resistance profile). ### Treatment Thresholds (APASL/EASL Guidelines) - **HBeAg-positive cirrhosis:** Treat if HBV DNA >2000 IU/mL - **HBeAg-negative cirrhosis:** Treat if HBV DNA >2000 IU/mL (or even lower in decompensated disease) - **Decompensated cirrhosis:** Treat regardless of HBV DNA level **Mnemonic:** **VLOAD** = **V**iral **LOAD** = HBV DNA quantification by PCR.